KROS — Keros Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $594.96m
- $35.03m
- $3.55m
- 54
- 16
- 13
- 16
Annual income statement for Keros Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 20.1 | 0 | 0.151 | 3.55 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 46.7 | 76.5 | 115 | 170 | 214 |
| Operating Profit | -46.7 | -56.4 | -115 | -170 | -211 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -45.5 | -56.7 | -105 | -153 | -187 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -45.5 | -58.7 | -105 | -153 | -187 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -45.4 | -58.7 | -105 | -153 | -187 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -45.4 | -58.7 | -105 | -153 | -187 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.94 | -2.52 | -4.15 | -5.2 | -5 |